Local Treatment of Chronic Candidiasis Stomatitis

Nikolishyna, E. V.; Марченко, А. В.; Иленко, Наталия Николаевна; Lytovchenko, I. Yu.

doi:10.26693/jmbs05.02.121

Cited by 5 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Планктонні та плівкові форми клінічних ізолятів Candida albicans ефективно знищуються розчинами поверхнево-активних антисептиків: 0,12% хлоргексидину біглюконату, 0,07-0,075% цетилперидинію, які входять до складу ополіскувачів ротової порожнини [12]. Для топічної терапії також рекомендують використовувати розчини барвників (метиленового синього, фукарцилу), борної кислоти, йодофори (йодінол) та поверхнево-активні антисептики [13]. Слід відзначити, що вітчизняні протоколи містять узагальнену інформацію без чітких рекомендацій та, безумовно, не відповідають вимогам сучасності в умовах великого арсеналу протигрибкових препаратів та не враховують накопичені повідомлення про розвиток резистентних форм грибів [14,15].…”

Section: Discussionunclassified

“…Planktonic and film forms of clinical isolates of Candida albicans are effectively destroyed by solutions of surface-active antiseptics: 0.12% chlorhexidine bigluconate, 0.07-0.075% cetylpyridinium, which are part of mouthwashes [12]. For topical therapy, it is also recommended to use solutions of dyes (methylene blue, fucarcyl), boric acid, iodophores (iodinol) and surface-active antiseptics [13]. It should be noted that domestic protocols contain generalised information without clear recommendations and certainly do not meet the requirements of the present day in the context of a large arsenal of antifungal drugs and do not take into account the accumulated reports on the development of resistant forms of fungi [14,15].…”

Section: мікробіологія / Microbiologymentioning

confidence: 99%

See 1 more Smart Citation

Sensitivity of the Pathogens, Causing Oral Candidasis, to Antimicrobial Agents

Sukmanskaya,

Yura

2023

VPBM

View full text Add to dashboard Cite

tics, orthopedic treatment and prevention of pathology of the maxillofacial system" (state registration number 0119U103951).Introduction.Candidiasis of the oral cavity is an opportunistic mycosis, the development of which depends on many factors. Yeast-like fungi of the genus Candida are representatives of the oral cavity microbiome from 40-60% to 80% of healthy people [1,2]. As a result of dysbiotic disturbances due to taking antibiotics, a decrease in the resistance properties of the body at the local and/or systemic level, associated with age factors, therapy with glucocorticosteroids, cytostatics, immunosuppressants, etc., the development of acquired immunodeficiencies, mechanical trauma of the mucous membrane due to wearing prostheses and many other factors, there is a

show abstract

Section: Discussionunclassified

Section: мікробіологія / Microbiologymentioning

confidence: 99%

Sensitivity of the Pathogens, Causing Oral Candidasis, to Antimicrobial Agents

Sukmanskaya,

Yura

2023

VPBM

View full text Add to dashboard Cite

show abstract

“…Лікування кандидамікозу СОПР повинно бути комплексним, припускає вплив на етіологічний чинник, патогенез та симптоматичні заходи [15,16,17,18].…”

Section: основна частинаunclassified

“…3) порушують синтез нуклеїнових кислот і білка (грізеофульвін) Класифікація за призначенням: а) препарати, які призначають при захворюваннях, що викликані патогенними грибами: полієнові антибіотики, похідні імідазолу, триазолу, грізеофульвін, препарати йоду, кислоти ундецилової, похідні N-метил-нафтиліну; б) препарати, які призначають при захворюваннях, що викликані умовно патогенними грибами: полієни, похідні імідазолу, триазолу, бісчетвертинні амонієві солі (меламін), галогени, неорганічні кислоти, луги [15].…”

Section: основна частинаunclassified

Clinical and Pharmacological Aspects of Antifungal Agents in Stomatologycal Practice

Ostrovska¹,

Moisieieva²,

Луценко³

et al. 2023

Act. Probl. of the Modern Med.

View full text Add to dashboard Cite

According to the World Health Organization, fungal infections account for 20-70% of diseases worldwide. This high prevalence is influenced significantly by social, medical, and pharmacological factors. Treating candidiasis poses challenges due to the characteristics of the causative agent, its adaptability to environmental conditions, and resistance to commonly used drugs. The increased occurrence of fungal infections in the oral cavity can be attributed to various risk factors such as prosthetic surface adhesion, poor habits, altered oral cavity pH, saliva quantity, iatrogenic factors, and comorbidities in patients. Candidal stomatitis treatment is complicated by the Candida genus's tolerance to traditional antifungal drugs, decreased immune reactivity, and the lack of effective treatment and prevention strategies for candidiasis in patients receiving antibacterial drugs and glucocorticosteroids. It is important to recognize that candidiasis is often a symptom of underlying conditions, emphasizing the need for a comprehensive approach, caution, and extensive knowledge in its treatment. Dentists dealing with mycosis-related issues play a crucial role in enhancing antifungal therapy and developing evidence-based pharmacotherapy standards. Therefore, it is essential to keep healthcare professionals informed about the clinical and pharmacological characteristics of antifungal drugs in a timely manner. This study aims to analyze contemporary literature regarding the clinical and pharmacological aspects of antifungal drugs in dental practice. The analysis of existing sources highlights several widely accepted principles of pharmacotherapy for fungal lesions of the oral mucosa, including selecting antifungal drugs based on their selectivity against specific pathogens or using combination therapies. Other factors to consider are the underlying cause of the disease, patient age, comorbidities, and the pharmacokinetics and toxicity profile of antifungal agents. Effective treatment of fungal infections requires a combination of local and systemic approaches, adhering strictly to prescribed drug dosages and treatment durations. The task for practicing clinicians facing challenges in managing oral mucosal mycoses is to enhance therapy using currently available antifungals and develop modern pharmacotherapy standards based on evidence-based medicine

show abstract

“…За даними літератури, важливим напрямком боротьби з набутою резистентністю є поєднання декількох препаратів із різним механізмом дії. У такому разі ризик одночасного утворення мутацій, які б призвели до формування резистентності до декількох препаратів набагато менший від ризику формування резистентності до кожного препарату окремо [3]. Найбільш застосовуваними на сьогодні при кандидозних ураженнях антифунгальними засобами є імідазоли та тріазоли, механізм дії яких полягає в пригніченні біосинтезу ергостеролу, незамінного для підтримання структурної цілісності мембран клітин грибів.…”

unclassified

The Influence of Medicinal and Aromatic Plants Extracts on the Antifungal Effect of Fluconazole Regarding C. Albicans and C. Tropicalis Isolated From Patients With Denture Stomatits

Kutsyk,

Ohiienko,

Cheliy

et al. 2023

Scientific and practical journal

View full text Add to dashboard Cite

Candida albicans is one of the most common and virulent representatives of Candida fungi which causes fungal lesions of the mucous membranes predominantly in people with compromised immune system. Candida resistance to classical antifungals such as polyenes, azoles, allylamines is a serious practical problem. Imidazole and triazole are the most commonly used antifungal agents for candidiasis today. Their mechanism of action lies in the inhibition of ergosterol biosynthesis which is indispensable for maintaining the structural integrity of fungal cell membranes. Activation of elimination systems is often associated with changes in the structure of fungal membranes, leading to a decrease in the supply of azoles into the fungal cell Screening of antifungal activity and synergism of antifungal activity of 166 aqueous-ethanol plant extracts with Fluconazole in relation to 2 clinical strains of Candida fungi (C.) (C. albicans and C. tropicalis) with different mechanisms of azole resistance isolated from patients with prosthetic stomatitis was conducted by means of agar diffusion method. The expressed direct antifungal activity of extracts of Calendula officinalis L. inflorescences, flowers of Limonium platyphyllum Lincz., flowers of Grataegus monogyna Jacq., roots of Potentilla repens L., the grass of Melilotus albus Medik, leaves of Peucedanum ruthenicum Bieb, leaves of Rhus coriaria L. and aerial part of Polythridum commune Hedw was determined in reference to the tested strains. Synergism of antifungal action with 1/4, 1/8 and 1/32 of Fluconazole MIC (minimal inhibiting concentration) in relation to both test strains of yeast-like Candida fungi was demonstrated by the flowers of Calendula officinalis L, aerial part of Melilotus albus Medik. The main purpose of the screening was to discriminate extracts in order to select those that would be promising for further testing by a more accurate сheckerboard titration method. The efflux mechanism of resistance to triazoles (in C. tropicalis test strain) is more susceptible to modification by biologically active compounds of medicinal plants. Regarding C. albicans test strain which combines the efflux mechanism of resistance with mutation(s) of ergosterol biosynthesis enzymes, the modifying effect of plant extracts is much less frequent and less pronounced. Therefore, it may be assumed that mutations of ergosterol biosynthesis enzymes provide high stability of the phenotypic manifestation of Candida azole resistance. Should that be the case, determining the azole resistance mechanism of Candida clinical isolates may be important for clinical practice. Combination therapy is more beneficial than monotherapy because it may provide more effective destruction or suppression of pathogens. The combined action of synergistic agents is quite easy to achieve in case of localized superficial lesions (which occur on the mucous membranes of the prosthetic bed in candidal prosthetic stomatitis): for example, using a systemic antifungal agent and a topical agent that contains a modifier of resistance of plant origin fungi. Synergistic interactions will increase the therapeutic efficacy of drugs, reduce the likelihood of resistance occurrence or further development, and will reduce dose-related toxicity.

show abstract

Local Treatment of Chronic Candidiasis Stomatitis

Cited by 5 publications

References 3 publications

Sensitivity of the Pathogens, Causing Oral Candidasis, to Antimicrobial Agents

Sensitivity of the Pathogens, Causing Oral Candidasis, to Antimicrobial Agents

Clinical and Pharmacological Aspects of Antifungal Agents in Stomatologycal Practice

The Influence of Medicinal and Aromatic Plants Extracts on the Antifungal Effect of Fluconazole Regarding C. Albicans and C. Tropicalis Isolated From Patients With Denture Stomatits

Contact Info

Product

Resources

About